Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3

Editorial ||FREE PAPER||

Authors Garry Walsh

Published 15 September 2006 Volume 2006:2(3) Pages 227—228

Garry Walsh

Asthmatic and Allergic Inflammation Group, School of Medicine, University of Aberdeen, UK

The third issue of volume two of Therapeutics and Clinical Risk Management presents review articles and original research papers on a wide range of topics.

Download Article [PDF] 

Readers of this article also read:

Exemestane in early breast cancer: a review

Michael Untch, Christian Jackisch

Therapeutics and Clinical Risk Management 2008, 4:1295-1304

Published Date: 5 December 2008

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta, Tracy Prematta, Timothy J Craig

Therapeutics and Clinical Risk Management 2008, 4:975-982

Published Date: 10 October 2008

Raltegravir: first in class HIV integrase inhibitor

Zelalem Temesgen, Dawd S Siraj

Therapeutics and Clinical Risk Management 2008, 4:493-500

Published Date: 11 April 2008

Update on local anesthetics: focus on levobupivacaine

Crina L Burlacu, Donal J Buggy

Therapeutics and Clinical Risk Management 2008, 4:381-392

Published Date: 11 April 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Editorial || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:361-362

Published Date: 15 July 2007

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007